2024年11月29日,同济大学医学院附属东方医院周彩存教授牵头多位专家在Nature Reviews Clinical Oncology发表题为“The changing treatment landscape of EGFR-mutant non-small-cell lung cancer”的综述,全面回顾和分析EGFR突变NSCLC治疗领域...
英文标题:Targeting CD24 Enhances the Response to Third-Generation Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer 中文标题:靶向CD24可增强EGFR突变NSCLC对第三代TKI的反应 讲者:J. Liang(复旦大学附属中山医院...
Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Front Oncol. 2020 Dec 10;10:610923. doi: 10.3389/fonc.2020.610923. PMID: 33363040; PMCID: PMC7758444. [9] Zhang L ZH, Zhang Z, Yao W, et al. ACTIVE: Apatinib plus gefitinib versus placebo plus gefi...
近日,由同济大学附属上海市肺科医院胸外科姜格宁教授、张鹏教授团队发起的TEAM-LungMate 004临床研究,在国际知名学术期刊《Nature Communications》上发表最新成果“Neoadjuvant Afatinib for Stage III EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Study”。这是第一项关于第二代EGFR-TKI新辅助治疗EGFR突变型N...
2024年12月7日，中南大学湘雅医学院附属肿瘤医院张永昌教授团队在期刊《Heliyon》上发表了题为“Intrathecal Pemetrexed Improves Survival Outcomes in Previously Treated EGFR-Mutant Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases”的研究论文。研究结果表明，IP是治疗TKI耐药的表皮生长因子受体突变...
本次报道的论文来自阿斯利康AI工程总监Eliseo Papa带领的研究团队发表在nature communications上的Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer。这篇研究基于BIKG知识图谱构建推荐系统来寻找EGFR突变阳性非小细胞肺癌耐药机制的驱动因子。 1.背景...
Cholesterol synthesis disruption combined with a molecule targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer Transl Lung Cancer Res (IF=5.132) Published onlin…
Li YS, Jie GL, Wu YL. Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer. Ther Adv Med Oncol. 2023 Aug 31;15:17588359231193726. doi: 10.1177/17588359231193726. PMID: 37667782; PMCID: ...
1. Yufeng Li, Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer, Cell Communication and Signaling (2023) 21:71 2. 与爱共舞订阅号：又一个肺癌四代靶向药倒下，究竟谁能破解奥希替尼耐药？3. BLU-945 ...
EGFR（Epidermal Growth Factor Receptor，表皮生长因子受体）基因突变是非小细胞肺癌（non-small-cell lung cancer, NSCLC）中最常见的激活突变。一线奥希替尼是在2021年国内纳入医保的第三代靶向药物，是目前EGFR阳性晚期肺腺癌患者最常使用的靶向药物。EGFR靶向耐药后不再活检，或者再活检病理结果未出根据经验直接治疗...